Risk model predicts relapse after frontline blinatumomab in paediatric B-ALL

Epcoritamab induces deep and durable responses in chemotherapy-ineligible elderly patients with diffuse large B-cell lymphoma

Tafasitamab plus lenalidomide added to R-CHOP improves PFS in high-risk diffuse large B-cell lymphoma

Brentuximab vedotin added to CHEP improves response in CD30+ peripheral T-cell lymphomas

Blinatumomab replaces intensive chemo in high-risk paediatric ALL, improving survival

Fedratinib improves spleen and symptom responses with promising survival outcomes in MDS/MPN and CNL

Mezigdomide plus carfilzomib and dexamethasone delays disease progression in R/R multiple myeloma

Yoga improves mood, fatigue, and insomnia in cancer survivors following treatment

Tafasitamab plus lenalidomide and R-CHOP delays disease progression in aggressive B-cell lymphomas

Rituximab-based chemotherapy achieves strong outcomes without routine radiotherapy in stage I extranodal large B-cell lymphoma

Epcoritamab plus rituximab and lenalidomide improves efficacy in relapsed or refractory follicular lymphoma

Climate and environmental factors drive seasonal risk of invasive mucormycosis in haematologic malignancies